Clinical and Genetic Landscape of Glioblastoma, IDH ‐Wildtype With FGFR Gene Family Alterations
Cancer Science · 2026-05 · 117 (5) · 1455-1468
DOI: 10.1111/cas.70347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, online erschienen am 25.02.2026. Verfasst von Yasuhito Kegoya und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan. Hauptthemen laut MEDLINE: Glioblastoma, Isocitrate Dehydrogenase, Brain Neoplasms, Receptor, Fibroblast Growth Factor, Type 1. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Glioblastoma, isocitrate dehydrogenase wildtype (GBM, IDH‐wt), is a highly aggressive brain tumor with a poor prognosis. Alterations in the fibroblast growth factor receptor ( FGFR ) gene family—such as FGFR :: TACC fusions and FGFR1 mutations—have emerged as potential therapeutic targets; however, their clinical and genetic features in GBM, IDH‐wt remain unclear. We analyzed 1076 GBM, IDH‐wt cases using comprehensive genomic profiling data from the Center for Cancer Genomics and Advanced Therapeutics (C‐CAT) database in Japan. FGFR alterations were detected in 8.0% of patients, including FGFR :: TAC C fusions (3.3%) and FGFR1 mutations (2.9%). The FGFR :: TACC fusion‐positive group was older at diagnosis and showed higher frequencies of TERT promoter mutation and MDM2 amplification, and lower frequencies of EGFR amplification and TP53 mutation, compared with the fusion‐negative group. The FGFR1 mutation‐positive group was enriched for ATRX , NF1 , and PIK3CA mutations and had significantly fewer TERT promoter and PTEN mutations, compared with the mutation‐negative group. No significant differences in overall survival were observed, although both groups tended to have longer median overall survival compared with their respective negative groups. This study represents the largest genomic cohort to date of FGFR alterations in GBM, IDH‐wt. FGFR: : TACC fusion‐positive and FGFR1 mutation‐positive GBMs exhibited distinct genetic profiles, highlighting the clinical relevance of molecular subclassification and providing insight for future therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
- Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
- Department of General Thoracic Surgery and Endocrinological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
ORCID-Profile: Yoshihiro Otani, Shinichi Toyooka, Shuta Tomida, Shota Tanaka
Zitieren
APA
Kegoya, Y., Otani, Y., Mizuta, R., Ikemachi, R., Kamiura, M., Ishida, J., Toyooka, S., Ennishi, D., Tomida, S., & Tanaka, S. (2026). Clinical and Genetic Landscape of Glioblastoma, IDH ‐Wildtype With FGFR Gene Family Alterations. Cancer Science, 117(5), 1455-1468. https://doi.org/10.1111/cas.70347
Vancouver
Kegoya Y, Otani Y, Mizuta R, Ikemachi R, Kamiura M, Ishida J, et al. Clinical and Genetic Landscape of Glioblastoma, IDH ‐Wildtype With FGFR Gene Family Alterations. Cancer Science. 2026;117(5):1455-1468. doi:10.1111/cas.70347
BibTeX
@article{Kegoya2026,
author = {Kegoya, Yasuhito and Otani, Yoshihiro and Mizuta, Ryo and Ikemachi, Ryosuke and Kamiura, Mako and Ishida, Joji and Toyooka, Shinichi and Ennishi, Daisuke and Tomida, Shuta and Tanaka, Shota},
title = {Clinical and Genetic Landscape of Glioblastoma, IDH ‐Wildtype With FGFR Gene Family Alterations},
journal = {Cancer Science},
year = {2026},
volume = {117},
number = {5},
pages = {1455--1468},
doi = {10.1111/cas.70347}
}
EUVIMED